Endometrial cancer: reviving progesterone therapy in the molecular age.

Shujie Yang, Kristina W. Thiel, Koenraad De Geest, Kimberly K. Leslie

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Endometrial cancer is the most common gynecologic malignancy and represents a major health concern because overall five-year survival rates have not improved in the last three decades. A great deal of research demonstrates that the endometrium is extremely sensitive to hormones, and a shift in the estrogen:progesterone balance is the major cause for the development of endometrial cancer. Progestin-based therapy has proven effective in a subset of patients, particularly in situations where expression of progesterone receptor (PR) is maintained. However, this approach is not routinely used in the clinic in the U.S. for several reasons. For example, many endometrial tumors have lost PR expression, which limits the clinical application of progestin-based therapy. While the idea that restoring PR expression will resensitize tumors to progestin was proposed over 20 years ago, we only now have the molecular tools to accomplish this goal. Basic science research has revealed several pathways that govern the expression of PR at the DNA, RNA, and protein levels. In this article, we describe one current approach to restore expression of PR at the epigenetic level in endometrial cancer. While still in the preclinical stage, we believe this strategy to re-establish PR expression will result in resensitization of endometrial tumors to progestin therapy.

Original languageEnglish (US)
Pages (from-to)205-212
Number of pages8
JournalDiscovery medicine
Volume12
Issue number64
StatePublished - Sep 2011
Externally publishedYes

Fingerprint

Progesterone Receptors
Endometrial Neoplasms
Progesterone
Progestins
Neoplasms
Therapeutics
Endometrium
Research
Epigenomics
Estrogens
Survival Rate
Hormones
RNA
DNA
Health
Proteins

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Endometrial cancer : reviving progesterone therapy in the molecular age. / Yang, Shujie; Thiel, Kristina W.; De Geest, Koenraad; Leslie, Kimberly K.

In: Discovery medicine, Vol. 12, No. 64, 09.2011, p. 205-212.

Research output: Contribution to journalArticle

Yang, S, Thiel, KW, De Geest, K & Leslie, KK 2011, 'Endometrial cancer: reviving progesterone therapy in the molecular age.', Discovery medicine, vol. 12, no. 64, pp. 205-212.
Yang, Shujie ; Thiel, Kristina W. ; De Geest, Koenraad ; Leslie, Kimberly K. / Endometrial cancer : reviving progesterone therapy in the molecular age. In: Discovery medicine. 2011 ; Vol. 12, No. 64. pp. 205-212.
@article{3ed7d07d4b154662b8a87d0bf5b36377,
title = "Endometrial cancer: reviving progesterone therapy in the molecular age.",
abstract = "Endometrial cancer is the most common gynecologic malignancy and represents a major health concern because overall five-year survival rates have not improved in the last three decades. A great deal of research demonstrates that the endometrium is extremely sensitive to hormones, and a shift in the estrogen:progesterone balance is the major cause for the development of endometrial cancer. Progestin-based therapy has proven effective in a subset of patients, particularly in situations where expression of progesterone receptor (PR) is maintained. However, this approach is not routinely used in the clinic in the U.S. for several reasons. For example, many endometrial tumors have lost PR expression, which limits the clinical application of progestin-based therapy. While the idea that restoring PR expression will resensitize tumors to progestin was proposed over 20 years ago, we only now have the molecular tools to accomplish this goal. Basic science research has revealed several pathways that govern the expression of PR at the DNA, RNA, and protein levels. In this article, we describe one current approach to restore expression of PR at the epigenetic level in endometrial cancer. While still in the preclinical stage, we believe this strategy to re-establish PR expression will result in resensitization of endometrial tumors to progestin therapy.",
author = "Shujie Yang and Thiel, {Kristina W.} and {De Geest}, Koenraad and Leslie, {Kimberly K.}",
year = "2011",
month = "9",
language = "English (US)",
volume = "12",
pages = "205--212",
journal = "Discovery medicine",
issn = "1539-6509",
publisher = "Discovery Medicine",
number = "64",

}

TY - JOUR

T1 - Endometrial cancer

T2 - reviving progesterone therapy in the molecular age.

AU - Yang, Shujie

AU - Thiel, Kristina W.

AU - De Geest, Koenraad

AU - Leslie, Kimberly K.

PY - 2011/9

Y1 - 2011/9

N2 - Endometrial cancer is the most common gynecologic malignancy and represents a major health concern because overall five-year survival rates have not improved in the last three decades. A great deal of research demonstrates that the endometrium is extremely sensitive to hormones, and a shift in the estrogen:progesterone balance is the major cause for the development of endometrial cancer. Progestin-based therapy has proven effective in a subset of patients, particularly in situations where expression of progesterone receptor (PR) is maintained. However, this approach is not routinely used in the clinic in the U.S. for several reasons. For example, many endometrial tumors have lost PR expression, which limits the clinical application of progestin-based therapy. While the idea that restoring PR expression will resensitize tumors to progestin was proposed over 20 years ago, we only now have the molecular tools to accomplish this goal. Basic science research has revealed several pathways that govern the expression of PR at the DNA, RNA, and protein levels. In this article, we describe one current approach to restore expression of PR at the epigenetic level in endometrial cancer. While still in the preclinical stage, we believe this strategy to re-establish PR expression will result in resensitization of endometrial tumors to progestin therapy.

AB - Endometrial cancer is the most common gynecologic malignancy and represents a major health concern because overall five-year survival rates have not improved in the last three decades. A great deal of research demonstrates that the endometrium is extremely sensitive to hormones, and a shift in the estrogen:progesterone balance is the major cause for the development of endometrial cancer. Progestin-based therapy has proven effective in a subset of patients, particularly in situations where expression of progesterone receptor (PR) is maintained. However, this approach is not routinely used in the clinic in the U.S. for several reasons. For example, many endometrial tumors have lost PR expression, which limits the clinical application of progestin-based therapy. While the idea that restoring PR expression will resensitize tumors to progestin was proposed over 20 years ago, we only now have the molecular tools to accomplish this goal. Basic science research has revealed several pathways that govern the expression of PR at the DNA, RNA, and protein levels. In this article, we describe one current approach to restore expression of PR at the epigenetic level in endometrial cancer. While still in the preclinical stage, we believe this strategy to re-establish PR expression will result in resensitization of endometrial tumors to progestin therapy.

UR - http://www.scopus.com/inward/record.url?scp=84859727785&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859727785&partnerID=8YFLogxK

M3 - Article

C2 - 21955848

AN - SCOPUS:84859727785

VL - 12

SP - 205

EP - 212

JO - Discovery medicine

JF - Discovery medicine

SN - 1539-6509

IS - 64

ER -